Karma Biotechnologies is an oncology-focused company that is pioneering innovative approaches to treat solid tumors, with an initial emphasis on colorectal cancer. The company’s technology is centered around the targeted delivery of cytokines and biological agents, particularly interleukin-15 (IL-15), directly to tumor and metastatic sites. This localized approach is designed to minimize systemic toxicity, which is a common concern with traditional cancer therapies. By converting "cold" tumors into "hot" tumors, Karma aims to enhance the body’s immune response, enabling it to effectively eliminate cancer cells.

The team at Karma Biotechnologies comprises experts in various fields, including synthetic biology and molecular biology, who are dedicated to advancing the company’s therapeutic strategies. Their innovative use of lipid nanoparticles (LNPs) for the delivery of therapeutic agents is a key component of their approach, allowing for precise targeting and improved efficacy in cancer treatment. With a strong leadership team and a commitment to developing cutting-edge solutions, Karma Biotechnologies is positioned to make significant contributions to the field of oncology.

United States

Karma is a proud IndieBio company! We're thrilled to be in the current IBSF14 cohort.

Metastatic cancer can be cured by cytokine immunotherapies, but only for a lucky few (about 7% of patients). Karma is making these medicines safe and effective for the other 93% by engineering immune cells to manufacture cytokines and other biologicals locally within the tumor, exactly where they're needed.

Karma Biotechnologies

Company Details